Physician profile
Robert A Zoltowski
NPI 1518081116
$12,173.98
in general payments reported to CMS, 2019-2025
32 companies · $495 in 2025
The $495 reported for 2025 was more than what a typical Psychiatry provider received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,769 · 2020: $1,858 · 2021: $2,622 · 2022: $2,987 · 2023: $2,047 · 2024: $395 · 2025: $495.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,938.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,937.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sunovion Pharmaceuticals INC. | $1,592.65 | 2019-2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,583.65 | 2020-2024 | Caplyta |
| Jazz Pharmaceuticals INC. | $917.42 | 2019-2023 | |
| Lundbeck LLC | $834.59 | 2019-2025 | Rexulti |
| Otsuka America Pharmaceutical, INC. | $812.71 | 2019-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Tris Pharma INC | $766.57 | 2019-2024 | Dyanavel Xr |
| Takeda Pharmaceuticals U.S.A., INC. | $748.16 | 2020-2024 | Trintellix |
| Abbvie INC. | $650.43 | 2021-2024 | Vraylar |
| Alkermes, INC. | $598.96 | 2021-2025 | Aristada, Lybalvi, Vivitrol |
| Corium, LLC | $587.40 | 2022-2025 | Azstarys |
| Janssen Pharmaceuticals, INC | $553.23 | 2019-2022 | |
| Ironshore Pharmaceuticals INC. | $319.57 | 2019-2023 | Jornay Pm |
| Almatica Pharma LLC | $237.33 | 2021-2023 | Loreev Xr, Sertraline Hcl |
| Idorsia Pharmaceuticals US INC | $216.84 | 2022-2023 | Quviviq |
| Axsome Therapeutics, INC. | $212.20 | 2022-2025 | Auvelity, Sunosi |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch Health US, LLC | $193.89 | 2019-2022 | |
| Validus Pharmaceuticals LLC | $187.82 | 2022-2025 | Equetro, Raldesy |
| Neos Therapeutics, LP | $149.63 | 2019-2025 | Exxua, Adzenys Xr-Odt |
| Neurocrine Biosciences, INC. | $143.49 | 2022-2025 | Ingrezza |
| Supernus Pharmaceuticals, INC. | $140.34 | 2022-2023 | Qelbree |
| Shire North American Group INC | $128.20 | 2019 | |
| Biogen, INC. | $107.25 | 2021-2022 | |
| E.R. Squibb & Sons, L.L.C. | $91.78 | 2025 | Cobenfy |
| Vanda Pharmaceuticals INC. | $88.39 | 2020-2025 | Fanapt |
| Eisai INC. | $66.76 | 2020 | |
| Indivior INC. | $53.84 | 2019 | |
| Harmony Biosciences LLC | $50.65 | 2020-2021 | |
| Alfasigma USA, INC. | $50.35 | 2020 | |
| Owp Pharmaceuticals, INC. | $40.76 | 2022-2023 | Subvenite, Lamotrigine |
| Livanova USA, INC. | $17.84 | 2020 | |
| Avanir Pharmaceuticals, INC. | $17.29 | 2019 | |
| Allergan, INC. | $13.99 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Zoltowski listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.